P. Wijngaard

From network analysis to experimental validation: identification of regulators of non-muscle myosin II contractility using the folded-gastrulation signaling pathway

Andy Zhao, Sophia Varady, Madelyn O’Kelley-Bangsberg, Vicki Deng et autres

The morphogenetic process of apical constriction, which relies on non-muscle myosin II (NMII) generated constriction of apical domains of epithelial cells, is key to the development of complex cellular patterns. Apical constriction occurs in almost all multicellular organisms, but one of the …

us (code pays fourni par la source)

From network analysis to experimental validation: identification of regulators of non-muscle myosin II contractility using the folded-gastrulation signaling pathway

Andy Zhao, Sophia Varady, Madelyn O’Kelley-Bangsberg, Vicki Deng et autres

Abstract The morphogenetic process of apical constriction, which relies on non-muscle myosin II (NMII) generated constriction of apical domains of epithelial cells, is key to the development of complex cellular patterns. Apical constriction occurs in almost all multicellular organisms, but one of …

us (code pays fourni par la source)

Inter-Individual Variability in LDL-C Reductions With Inclisiran—Pooled Data From ORION-10 and ORION-11

Peter James Psaltis, Scott Mitchell Wright, Frederick Johan Raal, David G. Kallend et autres

au, us, Afrique du Sud, de, ca, nl, gb (code pays fourni par la source)

Pooled Safety and Efficacy of Inclisiran in Patients With Statin Intolerance (ORION-10 and ORION-11)

B. McQuillan, R. Scott Wright, David G. Kallend, Frederick Johan Raal et autres

au, us, Afrique du Sud, de, ca, nl, gb (code pays fourni par la source)

Baseline Triglycerides and Non-HDL-C and apoB Goal Attainment in the ORION-10 and ORION-11 Trials

Eng Lee Ooi, Kausik Kumar Ray, David G. Kallend, Frederick Johan Raal et autres

au, gb, us, Afrique du Sud, de, ca, nl (code pays fourni par la source)

Efficacy and Safety of Inclisiran According to Age: A Pooled Analysis of Phase III Studies (ORION 9, 10 and 11)

David Martin Colquhoun, R. Scott Wright, Kausik Kumar Ray, Frederick Johan Raal et autres

au, us, gb, Afrique du Sud, de, ca, nl (code pays fourni par la source)

Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial

Kausik Kumar Ray, David G. Kallend, Lawrence A. Leiter, Frederick Johan Raal et autres

gb, ca, Afrique du Sud, de, us, nl (code pays fourni par la source)

Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia

Frederick Johan Raal, David G. Kallend, Kausik Kumar Ray, Traci A. Turner et autres

Afrique du Sud, ca, gb, us, de, nl (code pays fourni par la source)

Baseline triglycerides and non-HDL-C and apoB goal attainment in the ORION-10 and ORION-11 trials

Kausik Kumar Ray, David G. Kallend, Frederick Johan Raal, Robert M. Stoekenbroek et autres

Abstract Introduction Elevated triglyceride (TG) levels contribute to the total burden of circulating atherogenic lipoprotein levels and are associated with increased cardiovascular (CV) risk. LDL-C underestimates risk in patients with elevated TG. Therefore, 2019 ESC/EAS guidelines recommend apoB or non-HDL-C as secondary …

gb, us, Afrique du Sud, de, ca, nl (code pays fourni par la source)

Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11)

R. Scott Wright, David G. Kallend, Frederick Johan Raal, Robert M. Stoekenbroek et autres

Abstract Introduction Statin-associated side effects prevent a substantial proportion of patients from being adequately treated with statin therapy and achieving adequate LDL-C reductions. Phase 3 trials showed that inclisiran, a new siRNA, durably lowers LDL-C by ≥50% on top of maximally tolerated …

us, Afrique du Sud, de, ca, nl, gb (code pays fourni par la source)

Inter-individual variability in LDL-C reductions with inclisiran – data from ORION-10 and ORION-11

R. Scott Wright, Frederick Johan Raal, David G. Kallend, Robert M. Stoekenbroek et autres

Abstract Introduction Inclisiran, an investigational siRNA, has been shown to effectively and durably lower LDL-C in Phase 3 trials. Inter-individual variability in LDL-C reductions has been documented for statin therapy and ezetimibe. Purpose To evaluate the inter-individual variability in LDL-C lowering with …

us, Afrique du Sud, de, ca, nl, gb (code pays fourni par la source)

Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1.

Ulf Landmesser, Arash Haghikia, LA Leiter, R. Wright et autres